Review
. 2019 Jul; 20(7):e390-e396.
doi: 10.1016/S1470-2045(19)30158-5.

Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers

Lajos Pusztai 1 Julia Foldi 2 Arjun Dhawan 2 Michael P DiGiovanna 2 Eleftherios P Mamounas 3 
Affiliations
  • PMID: 31267973
  •     13 citations

Abstract

Important results are emerging from clinical trials showing that surgery followed by chemotherapy might not be the optimal strategy to maximise a patient's chance of survival from triple-negative or HER2-positive breast cancers. Administering chemotherapy before surgery provides an opportunity to directly observe the efficacy of a particular chemotherapy regimen. Patients who have extensive residual invasive cancer after neoadjuvant chemotherapy are at a high risk of recurrence for metastatic disease, which, in turn, make these patients ideal candidates for clinical trials. Two important clinical trials, CREATE-X (UMIN000000843) and KATHERINE (NCT01772472), have shown improved disease-free survival with postoperative capecitabine and ado-trastuzumab emtansine in patients with either triple-negative or HER2-positive breast cancer who had residual disease after neoadjuvant chemotherapy. The opportunity for residual-disease guided therapy, as observed in these trials, is lost when patients undergo surgery first. In this Personal View, we discuss the clinical implications of the CREATE-X and KATHERINE trials and place them into context with other developments in the adjuvant setting of early-stage breast cancer. We suggest that neoadjuvant systemic therapy should be considered as the new standard of care for HER2-positive and oestrogen receptor negative breast cancer, even for patients who present with operable (T1 or T2) disease.

Overuse of Neo-adjuvant Chemotherapy for Primary Breast Cancer.
Nikita Wadhwani, Ismail Jatoi.
Indian J Surg Oncol, 2020 Mar 25; 11(1). PMID: 32205961    Free PMC article.
Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer.
Alaknanda Adwal, Priyakshi Kalita-de Croft, +7 authors, Jodi M Saunus.
Life Sci Alliance, 2020 May 20; 3(7). PMID: 32423906    Free PMC article.
Long noncoding RNA LINC00115 promotes breast cancer metastasis by inhibiting miR-7.
Chunlei Yuan, Xuliang Luo, Sijia Duan, Liangyun Guo.
FEBS Open Bio, 2020 Mar 17; 10(7). PMID: 32175684    Free PMC article.
Machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy.
Roberto Lo Gullo, Sarah Eskreis-Winkler, Elizabeth A Morris, Katja Pinker.
Breast, 2019 Dec 02; 49. PMID: 31786416    Free PMC article.
Review.
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
Matteo Lambertini, Dominique Agbor-Tarh, +12 authors, Evandro de Azambuja.
ESMO Open, 2020 Nov 07; 5(6). PMID: 33154022    Free PMC article.
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
Natalia Kunst, Shi-Yi Wang, +4 authors, Lajos Pusztai.
JAMA Netw Open, 2020 Nov 24; 3(11). PMID: 33226431    Free PMC article.
Prognostic value of using glucosylceramide synthase and cytochrome P450 family 1 subfamily A1 expression levels for patients with triple-negative breast cancer following neoadjuvant chemotherapy.
Jiannan Liu, Shuhua Wang, +2 authors, Ping Sun.
Exp Ther Med, 2021 Feb 20; 21(3). PMID: 33603855    Free PMC article.
Recent advances in neoadjuvant therapy for breast cancer.
David A Potter, César A Herrera-Ponzanelli, +5 authors, Douglas Yee.
Fac Rev, 2021 Mar 05; 10. PMID: 33659921    Free PMC article.
Review.
PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy.
Beatriz Grandal, Manon Mangiardi-Veltin, +12 authors, Anne-Sophie Hamy.
Cancers (Basel), 2021 Mar 07; 13(4). PMID: 33670162    Free PMC article.
Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer.
A Matikas, K Wang, +18 authors, T Foukakis.
ESMO Open, 2021 Mar 14; 6(2). PMID: 33714010    Free PMC article.
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
Milos Holanek, Iveta Selingerova, +10 authors, Alexandr Poprach.
Cancers (Basel), 2021 Apr 04; 13(7). PMID: 33808149    Free PMC article.
3T DCE-MRI Radiomics Improves Predictive Models of Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Stefania Montemezzi, Giulio Benetti, +7 authors, Carlo Cavedon.
Front Oncol, 2021 May 08; 11. PMID: 33959498    Free PMC article.
Efficacy and safety of Kanglaite injection combined with chemotherapy for women breast cancer: A protocol for systematic review and meta-analysis of randomized clinical trials.
Shengli Cheng, Biao Qu, +3 authors, Jiahu Hao.
Medicine (Baltimore), 2021 Jun 05; 100(22). PMID: 34087912    Free PMC article.